Triamcinolone Acetonide as an Adjunctive to VPDT in ARMD.

Triamcinolone Acetonide as an Adjunctive Treatment to Verteporfin Therapy in Neovascular Age-Related Macular Degeneration: Randomized Placebo-Controlled Clinical Trial.

Status

UNKNOWN

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00148551

Enrollment

120

Registered

2005-09-08

Start date

2004-01-31

Completion date

2008-03-31

Last updated

2007-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age-Related Macular Degeneration

Keywords

AMD, Triamcinolone, Macular Degeneration

Brief summary

A 24 - month Study looking at the the changes in visual acuity of patients receiving PDT therapy in conjunction with intravitreal triamcinolone.

Detailed description

This study will evaluate the effect of Triamcinolone Acetonide in conjunction with photodynamic therapy for the treatment of sub-foveal choroidal neovascular membranes secondary to age-related macular degeneration.

Interventions

DRUGTriamcinolone Acetonide

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

* Individuals with predominantly classic, subfoveal CNV secondary to AMD. * No previous PDT Treatment in study eye.

Exclusion criteria

* CNV from conditions, other than AMD. * Other disease that could be responsible for decreased vision.

Design outcomes

Primary

Measure	Time frame
Changes in visual acuity from baseline.	—

Secondary

Measure	Time frame
Change in lesion characteristics from baseline.	—

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 2, 2026